Interleukin-18 receptor complex and B-lymphocyte antigen CD20 (IL-18R/CD20)

The Interleukin-18 receptor complex and B-lymphocyte antigen CD20 represent a dual-target therapeutic framework primarily utilized in the treatment of B-cell malignancies and autoimmune diseases. The IL-18 receptor complex is a heterodimer composed of the IL-18Rα (IL18R1) and IL-18Rβ (IL18RAP) subunits, which are members of the interleukin-1 receptor family expressed on NK cells and T cells (UniProt Q13478, O95256). Upon activation by its ligand IL-18, the receptor complex triggers pro-inflammatory signaling that enhances the production of interferon-gamma and the cytolytic activity of immune effector cells. CD20 (MS4A1) is a surface antigen expressed on mature B cells that regulates B-cell activation and calcium flux, making it a primary target for monoclonal antibodies like Rituximab (UniProt P11836). While these are distinct molecular entities, they are frequently studied in combination to enhance the efficacy of B-cell depletion therapies. IL-18 signaling has been shown to significantly augment the antibody-dependent cellular cytotoxicity (ADCC) of anti-CD20 antibodies by activating NK cells within the tumor microenvironment (PubMed PMID: 16116184). This synergistic approach is being explored through combination regimens, immunocytokines (e.g., anti-CD20-IL-18 fusion proteins), and next-generation CAR-T cells that secrete IL-18 to improve outcomes in patients with refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. Co-targeting these pathways aims to overcome immune evasion and provide more robust anti-tumor responses compared to CD20-targeted monotherapy.

Other names

IL18RIL18R1IL18RAPMS4A1CD20B-lymphocyte surface antigen B1CD218aCD218bIL-1RrpAcPL

CD20-targeted monoclonal antibodies induce B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. IL-18 receptor signaling activates NK cells and Th1 cells, promoting interferon-gamma production and enhancing the cytotoxic activity of immune effector cells against target cells.